Zydus Lifesciences Silodosin capsules are indicated to treat signs and symptoms of an enlarged prostate gland, which is also known as benign enlargement of the prostate, whereas Pregabalin capsules are indicated to treat pain caused by nerve damage due to diabetes or shingles
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Silodosin Capsules, 4 mg and 8 mg. The company also received the final approval to market Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg (USRLD: Lyrica capsules). Ropivacaine Hydrochloride Monohydrate
Silodosin capsules are indicated to treat signs and symptoms of an enlarged prostate gland, which is also known as benign enlargement of the prostate (benign prostatic hyperplasia or BPH). Silodosin capsules had annual sales of USD 14 million in the United States according to IQVIA data (IQVIA MAT Sep 2022).
Whereas Pregabalin capsules are indicated to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. It is also used to treat nerve pain caused by spinal cord injury and pain in people with fibromyalgia.
Pregabalin capsules had annual sales of USD 242 million in the United States according to IQVIA data (IQVIA MAT Sep 2022).
The Zydus group now has 338 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04.
The pharma major's stock was trading 0.98 per cent lower at Rs 407.40 a piece as of 12:47 IST on Saturday.
Get Social! Follow us on your favourite social networking website.
Your e-mail iformation will not be shared with anyone else. And it will be used only to send out our latest news.
Azobisisobutyronitrile © Copyright BW Healthcareworld 2018. All Rights Reserved.